Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Bissonnette R, et al. Among authors: thaci d. J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514. doi: 10.1111/jdv.14878. Epub 2018 Mar 22. J Eur Acad Dermatol Venereol. 2018. PMID: 29444376 Free PMC article. Clinical Trial.
Topical calcineurin inhibitors for the treatment of vulvar dermatoses.
Goldstein AT, Thaçi D, Luger T. Goldstein AT, et al. Among authors: thaci d. Eur J Obstet Gynecol Reprod Biol. 2009 Sep;146(1):22-9. doi: 10.1016/j.ejogrb.2009.05.026. Epub 2009 Jul 23. Eur J Obstet Gynecol Reprod Biol. 2009. PMID: 19631446 Review.
Treatment of moderate-to-severe plaque psoriasis.
Salgo R, Thaçi D. Salgo R, et al. Among authors: thaci d. G Ital Dermatol Venereol. 2009 Dec;144(6):701-11. G Ital Dermatol Venereol. 2009. PMID: 19907408 Review.
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
Thaçi D, Ortonne JP, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, Saurat JH, Khemis A, Sprøgel P, Esslinger HU, Unnebrink K, Kupper H. Thaçi D, et al. Br J Dermatol. 2010 Aug;163(2):402-11. doi: 10.1111/j.1365-2133.2010.09791.x. Epub 2010 Apr 2. Br J Dermatol. 2010. PMID: 20377585 Clinical Trial.
The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle-controlled study.
Foelster Holst R, Reitamo S, Yankova R, Worm M, Kadurina M, Thaci D, Bieber T, Tsankov N, Enk A, Luger T, Duffy M, Tansley R. Foelster Holst R, et al. Among authors: thaci d. Allergy. 2010 Dec;65(12):1594-9. doi: 10.1111/j.1398-9995.2010.02417.x. Epub 2010 Sep 7. Allergy. 2010. PMID: 21039597 Clinical Trial.
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D. Ortonne JP, et al. Among authors: thaci d. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1012-20. doi: 10.1111/j.1468-3083.2010.03944.x. Epub 2011 Jan 9. J Eur Acad Dermatol Venereol. 2011. PMID: 21214631 Clinical Trial.
Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, Fichtlscherer S, Thaçi D, Boehncke WH. Boehncke S, et al. Among authors: thaci d. J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1187-93. doi: 10.1111/j.1468-3083.2010.03947.x. Epub 2011 Jan 17. J Eur Acad Dermatol Venereol. 2011. PMID: 21241371
307 results